Once again, there is controversy over an expensive drug for premature babies.
At issue are new American Academy of Pediatrics guidelines that recommend scaling back usage of a drug called Synagis, which costs several thousand dollars and is sold by AstraZeneca 'sAZN.LN -0.23% MedImmune unit, because evidence shows the medicine benefits few children other than the youngest premature infants.
Help employers find you! Check out all the jobs and post your resume.
